These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10628567)

  • 1. Yttrium-90-labeled human macroaggregated albumin for internal radiotherapy: combined use with DTPA.
    Watanabe N; Oriuchi N; Endo K; Inoue T; Tanada S; Murata H; Sasaki Y
    Nucl Med Biol; 1999 Oct; 26(7):847-51. PubMed ID: 10628567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of yttrium-90-labeled human macroaggregated albumin for regional radiotherapy.
    Watanabe N; Oriuchi N; Igarashi H; Higuchi T; Yukihiro M; Fukushima Y; Tomiyoshi K; Hirano T; Inoue T; Endo K
    Nucl Med Biol; 1997 Jul; 24(5):465-9. PubMed ID: 9290084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.
    Breeman WA; De Jong MT; De Blois E; Bernard BF; De Jong M; Krenning EP
    Nucl Med Biol; 2004 Aug; 31(6):821-4. PubMed ID: 15246375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect labeling of macroaggregated albumin with indium-111 via diethylenetriaminepentaacetic acid.
    Watanabe N; Shirakami Y; Tomiyoshi K; Oriuchi N; Hirano T; Yukihiro M; Inoue T; Endo K
    Nucl Med Biol; 1996 Jul; 23(5):595-8. PubMed ID: 8905824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM; Stolz B; Albert R; Ruser G; Briner U; Mäcke HR; Bruns C
    Nucl Med Biol; 1998 Apr; 25(3):181-8. PubMed ID: 9620621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic comparative evaluation of 90Y-labeled bifunctional chelators for their use in targeted therapy.
    Chakravarty R; Chakraborty S; Dash A
    J Labelled Comp Radiopharm; 2014 Feb; 57(2):65-74. PubMed ID: 24678528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapy.
    Pandey U; Mukherjee A; Sarma HD; Das T; Pillai MR; Venkatesh M
    Appl Radiat Isot; 2002 Sep; 57(3):313-8. PubMed ID: 12201136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium-86-labelled human serum albumin microspheres: relation of surface structure with in vivo stability.
    Schiller E; Bergmann R; Pietzsch J; Noll B; Sterger A; Johannsen B; Wunderlich G; Pietzsch HJ
    Nucl Med Biol; 2008 Feb; 35(2):227-32. PubMed ID: 18312833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 90Y-PET for the assessment of microsphere biodistribution after selective internal radiotherapy.
    Bagni O; D'Arienzo M; Chiaramida P; Chiacchiararelli L; Cannas P; D'Agostini A; Cianni R; Salvatori R; Scopinaro F
    Nucl Med Commun; 2012 Feb; 33(2):198-204. PubMed ID: 22124359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of indium-111 in human malignant tumor xenografts and control by chelators.
    Watanabe N; Oriuchi N; Endo K; Inoue T; Tanada S; Murata H; Kim EE; Sasaki Y
    Nucl Med Biol; 1999 Oct; 26(7):853-8. PubMed ID: 10628568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
    J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of radioactivity after injection of liver-targeted proteins labeled with 111In or 125I. Effect of labeling on distribution and excretion of radioactivity in rats.
    Staud F; Nishikawa M; Morimoto K; Takakura Y; Hashida M
    J Pharm Sci; 1999 Jun; 88(6):577-85. PubMed ID: 10350492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
    Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
    J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
    Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
    J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
    Keeling AA; Vaughan AT; Beaney RP
    Br J Cancer; 1989 Jul; 60(1):74-8. PubMed ID: 2803919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
    Sundberg AL; Gedda L; Orlova A; Bruskin A; Blomquist E; Carlsson J; Tolmachev V
    Cancer Biother Radiopharm; 2004 Apr; 19(2):195-204. PubMed ID: 15186600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
    Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.